Sight Sciences' newest MIGS device gains FDA clearance for single-pass canaloplasty and trabeculotomy in open-angle glaucoma.

New system expands the Company’s leadership in interventional glaucoma with the first FDA cleared MIGS device for single pass canaloplasty with TruSync™ Plus innovation.

Please provide your email address to receive an email when new articles are posted on . New devices, advancements in technology and unique MIGS approaches provide an expansive landscape for surgeons ...

Please provide your email address to receive an email when new articles are posted on . WAIKOLOA, Hawaii — With several good MIGS options, the choice often comes down to matching the procedure with ...

IRVINE, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for ...

iStar Medical just left its mark on the fast-growing market for minimally invasive glaucoma surgery (MIGS). The Wavre, Belgium-based company now has CE mark to launch its MINIject glaucoma implant in ...

Research and Markets has announced the addition of the "Global Micro-Invasive Glaucoma Surgery (MIGS) Devices Market (By Target, By Surgery, By End User, By Region, By Country): Opportunities and ...

Ivantis and Glaukos are no-doubt rivals in the Minimally Invasive Glaucoma Surgical space. The two companies’ technologies went head-to-head in the COMPARE study in 2019 and up until recently, both ...